HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Rodrigo Ruiz-Soto Selected Research

mirvetuximab soravtansine

11/2017Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine.
8/2017Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.
4/2017Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.
12/2016Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Rodrigo Ruiz-Soto Research Topics

Disease

13Neoplasms (Cancer)
12/2021 - 03/2014
6Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
10/2022 - 01/2019
4Ovarian Neoplasms (Ovarian Cancer)
11/2017 - 12/2016
3Disease Progression
11/2021 - 01/2020
2Fatigue
10/2020 - 01/2020
2Ovarian Epithelial Carcinoma
11/2017 - 12/2016
1Neoplasm Metastasis (Metastasis)
11/2021
1Anemia
11/2021
1Abdominal Pain (Pain, Abdominal)
11/2021
1Giant Cell Tumors (Giant Cell Tumor)
11/2021
1Myalgia
10/2020
1Nausea
10/2020
1Constipation
10/2020
1Alopecia (Baldness)
10/2020
1Diarrhea
10/2020
1Acute Kidney Injury (Acute Renal Failure)
01/2020
1Septic Shock (Toxic Shock Syndrome)
01/2020
1Dehydration (Water Stress)
01/2020
1Hypertension (High Blood Pressure)
01/2020
1Necrosis
12/2016
1Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
10/2016
1Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
06/2015
1Lymphoma (Lymphomas)
06/2015
1Colorectal Neoplasms (Colorectal Cancer)
02/2015
1Lung Neoplasms (Lung Cancer)
03/2014
1Circulating Neoplastic Cells
12/2013
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
12/2013
1Bronchopneumonia
12/2013
1Sepsis (Septicemia)
12/2013
1Ileus
12/2013
1Non-Hodgkin Lymphoma (Lymphosarcoma)
12/2005
1Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune)
06/2003

Drug/Important Bio-Agent (IBA)

8ripretinibIBA
10/2022 - 01/2019
4mirvetuximab soravtansineIBA
11/2017 - 12/2016
4Immunoconjugates (Immunoconjugate)IBA
11/2017 - 12/2016
3Phosphotransferases (Kinase)IBA
10/2022 - 06/2015
3Tyrosine Kinase InhibitorsIBA
12/2021 - 02/2015
3Folate Receptor 1IBA
11/2017 - 12/2016
3XL765IBA
06/2015 - 03/2014
2Imatinib Mesylate (Gleevec)FDA Link
10/2022 - 01/2020
2Biomarkers (Surrogate Marker)IBA
11/2021 - 03/2014
2Maytansine (Maitansine)IBA
04/2017 - 12/2016
2PlatinumIBA
04/2017 - 12/2016
2Phosphatidylinositols (Phosphatidylinositol)IBA
06/2015 - 05/2014
2TOR Serine-Threonine KinasesIBA
06/2015 - 03/2014
2pazopanibFDA Link
02/2015 - 12/2013
1Circulating Tumor DNAIBA
12/2021
1AntibodiesIBA
11/2021
1Macrophage Colony-Stimulating FactorIBA
11/2021
1pexidartinibIBA
11/2021
1Oncogene Proteins (Oncogene Protein)IBA
10/2020
1Sunitinib (Sutent)FDA Link
01/2020
1Lipase (Acid Lipase)FDA Link
01/2020
1Pharmaceutical PreparationsIBA
01/2019
1Folic Acid (Vitamin M)FDA LinkGeneric
08/2017
1Monoclonal AntibodiesIBA
04/2017
1TubulinIBA
04/2017
1Bevacizumab (Avastin)FDA Link
12/2016
1Carboplatin (JM8)FDA LinkGeneric
12/2016
1Doxorubicin (Adriamycin)FDA LinkGeneric
12/2016
1Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA
06/2015
1Cetuximab (Erbitux)FDA Link
02/2015
1Irinotecan (Camptosar)FDA LinkGeneric
02/2015
1Mechanistic Target of Rapamycin Complex 1IBA
05/2014
1Mechanistic Target of Rapamycin Complex 2IBA
05/2014
1Erlotinib Hydrochloride (CP 358,774)FDA Link
03/2014
1Class I Phosphatidylinositol 3-KinasesIBA
03/2014
1ErbB Receptors (EGF Receptor)IBA
03/2014
1Mitogen-Activated Protein KinasesIBA
03/2014
1Cisplatin (Platino)FDA LinkGeneric
12/2013
1Pemetrexed (MTA)FDA Link
12/2013
1Member 1 Subfamily B ATP Binding Cassette TransporterIBA
06/2003
1Inosine Triphosphate (ITP)IBA
06/2003

Therapy/Procedure

5Therapeutics
11/2021 - 10/2016
1Duration of Therapy
11/2021
1Stem Cell Transplantation
12/2005